Parkinson’s Disease

Debate between Cameron Thomas and Paul Davies

Wednesday 21st May 2025 Westminster Hall

[Paul Davies]

I absolutely agree. This is not a case of placing people with Parkinson’s in the corner and providing them with medication; this is about helping them to lead full lives, improving their quality of life and aiding them to do what they want to do. I know from people I have met in the Parkinson’s community that that is exactly what they want to do, so I absolutely agree with my hon. Friend.

Early intervention can make a profound difference in how patients manage their condition and maintain their independence. For people with Parkinson’s, receiving medication on time—within 30 minutes of the prescribed schedule—is not a convenience; it is a necessity. Delays can lead to severe symptoms, including immobility, pain and, in extreme cases, life-threatening complications. However, more than half of hospitalised patients report problems receiving their medication on time.

[Cameron Thomas (Tewkesbury) (LD)]

A constituent of mine was diagnosed with Parkinson’s at the age of 61. Individual sufferers can experience the symptoms to varying degrees day by day, which brings into question the effectiveness of PIP assessments, the results of which can vary depending on when they are carried out. With medical assistance hard to come by, charities such as Parkinson’s UK and Cure Parkinson’s are vital to sufferers. Will the hon. Gentleman join me in thanking them and similar organisations for their support to these thousands of people across the country.

[Paul Davies]

I absolutely agree—the role they play is vital in terms of supporting this community. To be truthful, the people I have met in those groups are inspirational, as is the work they do, so I thank them for that.

NHS England’s medicine safety improvement programme, running from 2024 to 2027, is a welcome step. It aims to ensure that time-critical medications are administered promptly in hospitals, but we must ensure that the programme is fully implemented and that its findings are acted upon across all NHS trusts. Timely medication is a basic right for Parkinson’s patients, and we must treat it as such. In England, people with Parkinson’s still face prescription charges, unlike in Wales, Scotland and Northern Ireland. These charges can be a significant burden, especially for working-age patients, who may already face reduced income due to their condition. Research shows that eliminating these charges could reduce hospital admissions and save the NHS money, but Parkinson’s remains absent from the list of conditions exempt from charges—a list that has not been meaningfully updated in more than 60 years. It is time for a review. We must ensure that no one is forced to choose between their health and their finances.

New treatments such as Produodopa, which was approved for NHS use in 2024, offer hope for those with severe symptoms. This medication could be life-changing for patients whose symptoms are not well managed by the existing treatments. However, due to staffing and funding constraints, many hospitals are unable to offer it. We must ensure that all patients who need innovative treatments, such as Produodopa, can access them, and that the NHS is equipped to adopt new therapies quickly and equitably. Innovation must not be a postcode lottery.

I will now turn briefly to my constituency. Since being elected, I have had the privilege of meeting Dr Chris Ryan and Mrs Liz Ryan MBE. Over a cup of tea in February, they shared their experiences and highlighted the urgent need for better Parkinson’s care in Kirklees. Liz, who received an MBE for her services to education, continues to be a pillar of our community despite her diagnosis. Together they have organised local events, including a Parkinson’s choir that brings joy and support to many.

Following our meeting, I wrote to Kirklees council and Calderdale and Huddersfield NHS foundation trust to ask what more can be done. I also contacted the Department of Health and Social Care regarding regular consultations and better medication management, and the Minister informed me that the neurology service specification is being updated, and will be published later this year. Although remote consultations are helpful they are not always suitable for Parkinson’s patients, who require regular, holistic in-person care. I urge the Government to consult with Parkinson’s UK during this review.

I also had the pleasure of attending the Big Sing for Parkinson’s on World Parkinson’s Day. The event was organised by the “Movers & Shakers” podcast, and it was a celebration of community, resilience and hope. As I said earlier, it was absolutely inspirational; to witness that community, and the strength of community spirit and determination to drive through with their lives, was incredible. The group also published the Parky charter, outlining five key needs for people with Parkinson’s—needs that are still unmet. This year, two Big Sings were held: the one I attended in Huddersfield, and the other in London. They brought together people in solidarity and song.

As we move forward, let us remember that Parkinson’s Awareness Month is not just about raising awareness, but taking meaningful action. It is about listening to those with lived experience, supporting families and carers, and ensuring that our health system is equipped to meet the needs of every person living with Parkinson’s.

Parkinson’s is a condition that demands our attention, compassion and action. By addressing workforce shortages, supporting patients from diagnosis, ensuring timely medication, removing financial barriers, and embracing innovation, we can dramatically improve the lives of those living with Parkinson’s.